Origin of histotripsy
The science of histotripsy was developed by leading ultrasound scientists from the University of Michigan as a non-invasive potential alternative to certain surgical procedures.
The science of histotripsy was developed by leading ultrasound scientists from the University of Michigan as a non-invasive potential alternative to certain surgical procedures.
Leading multi-disciplinary clinicians from the University of Wisconsin and the University of Michigan collaborate through ongoing partnerships with HistoSonics to bring histotripsy into everyday clinical practice.
Chairman of the Board (HistoSonics) and Managing Director - Venture Investors, LLC
President, CEO - HistoSonics
Vice President - Johnson & Johnson Innovation – JJDC, Inc.
Former President - Medtronic Neuromodulation
Managing Director - Lumira Ventures
President and CEO - Silk Road Medical
Chief Medical Officer, Varian Interventional Solutions - Varian Medical Systems
Senior Medical Advisor - HistoSonics
Partner - Yonjin Venture
Premier provider of seed and early stage venture capital to healthcare companies.
Partners & invests in best-in-class innovative biotherapeutic & medtech entrepreneurs building transformative companies.
Applying human ingenuity to help you elevate cancer care.
Investing in and supporting the global entrepreneurial community to solve critical healthcare needs.
Specializes in early and mid-stage life science companies. We are interested in innovative technologies in therapeutics, diagnostics and medical devices.
Helps entrepreneurs define, develop, grow, and build value in their businesses, principally in medicine healthcare technology.
Investing in promising new ventures in emerging technologies with high growth potential.
Provides early stage venture capital to promising entrepreneurial companies in healthcare technology and other fields..
Building transformational human medicine companies that benefit patients and the professionals who serve them.